Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
Rhea-AI Summary
Alamar Biosciences (Nasdaq: ALMR) reported second quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, driven by 35% instrument growth to $7.8 million, 147% consumable growth to $15.5 million, and 49% services and other growth to $6.2 million.
Gross margin improved to 60% from 53%, while operating expenses rose 89% to $31.2 million, leading to an operating loss of $13.5 million and net loss of $13.2 million. Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million at June 30, 2026.
The company launched the NULISAseq Neuro 220 Panel with an eMTBR-tau assay, the Immune 340 Panel, and expanded its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. Alamar provided full-year 2026 revenue guidance of $116–$120 million, implying 59% year-over-year growth at the midpoint.
Positive
- Q2 2026 revenue up 82% year-over-year to $29.4 million
- Consumable revenue up 147% year-over-year to $15.5 million
- Gross margin expanded to 60% from 53% in prior-year quarter
- Strong liquidity with $256.3 million in cash, equivalents, investments and restricted cash
- 2026 revenue guidance of $116–$120 million, 59% growth at midpoint vs. 2025
Negative
- Q2 2026 operating loss widened to $13.5 million from $7.9 million
- Q2 2026 net loss increased to $13.2 million from $7.0 million
- Operating expenses rose 89% year-over-year to $31.2 million
- Year-to-date 2026 net loss of $34.5 million vs. $14.7 million in 2025
- Year-to-date 2026 loss on remeasurement of convertible notes totaled $10.0 million
News Explained
The June 30 balance sheet reports zero convertible preferred stock and positive equity instead of the year-end preferred-stock and deficit balances.
The company has reported its completed second-quarter results; as of
The same balance sheet reports convertible preferred stock at
Liquidity is separately reported as cash and cash equivalents of
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | 1Q26 earnings report | Positive | +1.3% | Revenue growth and improved gross margin accompanied IPO proceeds and continued losses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific earnings record showed positive alignment, with the prior report followed by a 1.27% 24-hour gain.
Key Terms
multiplexed immunoassay medical
stock-based compensation financial
convertible notes financial
proteomics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended June 30, 2026.
Recent Highlights
- Generated
$29.4 million of total revenue for the second quarter of 2026, an increase of82% as compared to the corresponding period of 2025 - Launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau, available in our NULISAseq™ Neuro 220 Panel and through our Technology Access Program, enabling scalable, non-invasive measurement of tau tangle burden
- Expanded strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to deliver a combined dataset of more than 140,000 samples
- Launched the NULISAseq™ Immune 340 Panel, our broadest multiplexed immune profiling solution for translational research and drug development
- Providing full-year 2026 revenue guidance of
$116 million to$120 million , representing growth of59% at the midpoint of the range as compared to 2025
"We delivered a strong second quarter with consumable revenue growing nearly
Second Quarter 2026 Financial Results
Revenue was
Gross margin was
Operating expenses were
Operating loss was
Net loss was
Cash, cash equivalents, short-term investments and restricted cash were
2026 Guidance
Alamar Biosciences expects full year 2026 revenue to be in the range of
Webcast Information
Alamar Biosciences will host a conference call to discuss the second quarter 2026 financial results after market close on Monday, August 10, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investors.alamarbio.com/.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Forward Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ estimates for the full year 2026, its financial outlook, future plans and prospects, its ability to accelerate adoption of its platform and establish a new gold standard in protein detection and analysis, its anticipated sustained momentum in revenue growth from the recent launches of eMTBR-tau and the Immune 340 Panel, and Alamar Biosciences’ ability to grow its business. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Investor contact:
investors@alamarbio.com
Media contact:
media@alamarbio.com
| Alamar Biosciences, Inc. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 23,269 | $ | 12,040 | $ | 44,610 | $ | 21,209 | |||||||
| Service and other revenue | 6,158 | 4,122 | 10,852 | 8,044 | |||||||||||
| Total revenue(1) | 29,427 | 16,162 | 55,462 | 29,253 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Cost of product revenue(2) | 9,858 | 6,489 | 19,668 | 11,860 | |||||||||||
| Cost of service and other revenue(2) | 1,851 | 1,092 | 3,619 | 2,423 | |||||||||||
| Total cost of revenue | 11,709 | 7,581 | 23,287 | 14,283 | |||||||||||
| Gross profit | 17,718 | 8,581 | 32,175 | 14,970 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development(2) | 13,817 | 8,895 | 26,834 | 17,197 | |||||||||||
| Selling, general and administrative(2) | 17,433 | 7,605 | 31,220 | 14,245 | |||||||||||
| Total operating expenses | 31,250 | 16,500 | 58,054 | 31,442 | |||||||||||
| Loss from operations | (13,532 | ) | (7,919 | ) | (25,879 | ) | (16,472 | ) | |||||||
| Interest income, net | 1,875 | 630 | 2,414 | 1,416 | |||||||||||
| Interest expense | (224 | ) | (48 | ) | (447 | ) | (94 | ) | |||||||
| Loss on remeasurement of convertible notes | (1,377 | ) | — | (9,971 | ) | — | |||||||||
| Other (expense) income, net | (34 | ) | 314 | (270 | ) | 468 | |||||||||
| Net loss before income tax | (13,292 | ) | (7,023 | ) | (34,153 | ) | (14,682 | ) | |||||||
| Provision for (benefit from) income taxes | (93 | ) | — | 371 | — | ||||||||||
| Net loss | $ | (13,199 | ) | $ | (7,023 | ) | $ | (34,524 | ) | $ | (14,682 | ) | |||
| Net loss per share, basic and diluted | $ | (0.22 | ) | $ | (0.62 | ) | $ | (0.97 | ) | $ | (1.30 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 58,665,055 | 11,409,556 | 35,589,492 | 11,334,630 | |||||||||||
(1) The following table represents revenue by source for the periods indicated:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Instruments | $ | 7,788 | $ | 5,773 | $ | 15,169 | $ | 9,919 | ||||||||
| Consumables | 15,481 | 6,267 | 29,441 | 11,290 | ||||||||||||
| Services | 6,158 | 4,122 | 10,852 | 7,794 | ||||||||||||
| Other revenue | — | — | — | 250 | ||||||||||||
| Total | $ | 29,427 | $ | 16,162 | $ | 55,462 | $ | 29,253 | ||||||||
(2) Includes stock-based compensation expense as follows:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Cost of product revenue | $ | 45 | $ | 7 | $ | 59 | $ | 15 | ||||||||
| Cost of service and other revenue | 58 | 12 | 80 | 25 | ||||||||||||
| Research and development | 838 | 262 | 1,230 | 491 | ||||||||||||
| Selling, general and administrative | 2,339 | 399 | 3,378 | 768 | ||||||||||||
| Total stock-based compensation expense | $ | 3,280 | $ | 680 | $ | 4,747 | $ | 1,299 | ||||||||
| Alamar Biosciences, Inc. Condensed Consolidated Balance Sheets (Unaudited, in thousands) | |||||||
| June 30, 2026 | December 31, 2025 | ||||||
| ASSETS | |||||||
| Current Assets | |||||||
| Cash and cash equivalents | $ | 132,969 | $ | 30,002 | |||
| Short-term investments | 117,083 | — | |||||
| Accounts receivable | 20,344 | 12,753 | |||||
| Inventory | 45,409 | 38,482 | |||||
| Prepaid expenses and other current assets | 15,577 | 13,468 | |||||
| Total current assets | 331,382 | 94,705 | |||||
| Restricted cash | 6,254 | 4,907 | |||||
| Property and equipment, net | 13,358 | 10,498 | |||||
| Operating lease right-of-use assets | 35,798 | 26,130 | |||||
| Capitalized software, net | 1,605 | 1,988 | |||||
| Other assets—noncurrent | 2,578 | 1,764 | |||||
| Total assets | $ | 390,975 | $ | 139,992 | |||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) | |||||||
| Current Liabilities | |||||||
| Accounts payable | $ | 13,790 | $ | 5,872 | |||
| Accrued and other current liabilities | 11,893 | 15,759 | |||||
| Short-term operating lease liabilities | 2,277 | 2,099 | |||||
| Total current liabilities | 27,960 | 23,730 | |||||
| Long-term operating lease liabilities | 39,182 | 29,564 | |||||
| Warrant liabilities | — | 247 | |||||
| Term debt | 9,947 | 9,810 | |||||
| Other noncurrent liabilities | 1,029 | 599 | |||||
| Total liabilities | 78,118 | 63,950 | |||||
| Convertible preferred stock | — | 234,996 | |||||
| Stockholders’ equity (deficit) | |||||||
| Founders preferred stock | — | — | |||||
| Common stock | 7 | 1 | |||||
| Additional paid-in capital | 516,288 | 9,892 | |||||
| Accumulated other comprehensive loss | (139 | ) | (72 | ) | |||
| Accumulated deficit | (203,299 | ) | (168,775 | ) | |||
| Total stockholders’ equity (deficit) | 312,857 | (158,954 | ) | ||||
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $ | 390,975 | $ | 139,992 | |||
